Andrea Gibson

2.7k total citations · 2 hit papers
43 papers, 2.0k citations indexed

About

Andrea Gibson is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Andrea Gibson has authored 43 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Ophthalmology, 22 papers in Radiology, Nuclear Medicine and Imaging and 14 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Andrea Gibson's work include Retinal Diseases and Treatments (21 papers), Retinal Imaging and Analysis (21 papers) and Retinal and Optic Conditions (14 papers). Andrea Gibson is often cited by papers focused on Retinal Diseases and Treatments (21 papers), Retinal Imaging and Analysis (21 papers) and Retinal and Optic Conditions (14 papers). Andrea Gibson collaborates with scholars based in United States, United Kingdom and Germany. Andrea Gibson's co-authors include David S. Boyer, David M. Brown, Quan Dong Nguyen, Dennis M. Marcus, Amy Chen Rundle, J. Jill Hopkins, Leonard Feiner, Roman G. Rubio, Jason S. Ehrlich and Sunil Patel and has published in prestigious journals such as Journal of Clinical Oncology, Ophthalmology and Medical Care.

In The Last Decade

Andrea Gibson

40 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ranibizumab for Diabetic Macular Edema

2012 1.2k citations Quan Dong Nguyen, David M. Brown et al. Ophthalmology profile →
Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy

2021 152 citations Kate Absolom, Lorraine Warrington et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrea Gibson United States	18	1.6k	1.3k	171	170	163	43	2.0k
Say‐Beng Tan Singapore	11	340 0.2×	540 0.4×	87 0.5×	43 0.3×	75 0.5×	16	1.2k
Joann Fontanarosa United States	12	297 0.2×	318 0.2×	164 1.0×	55 0.3×	77 0.5×	30	1.2k
Amanda Caissie Canada	13	124 0.1×	144 0.1×	187 1.1×	103 0.6×	99 0.6×	41	669
Ligia Fú Honduras	15	213 0.1×	79 0.1×	284 1.7×	101 0.6×	443 2.7×	23	866
Elena Nicod United Kingdom	21	262 0.2×	259 0.2×	28 0.2×	52 0.3×	56 0.3×	40	1.1k
Ping Hou China	20	234 0.1×	100 0.1×	219 1.3×	415 2.4×	56 0.3×	63	1.2k
Alexandra Smith Australia	13	78 0.0×	96 0.1×	62 0.4×	160 0.9×	215 1.3×	37	807
Mirjam E. Meltzer Netherlands	15	220 0.1×	156 0.1×	23 0.1×	40 0.2×	38 0.2×	21	965
Emily K. Tam United States	10	108 0.1×	86 0.1×	172 1.0×	58 0.3×	51 0.3×	20	477
Michelle Orme United Kingdom	19	60 0.0×	70 0.1×	109 0.6×	220 1.3×	103 0.6×	38	949

Countries citing papers authored by Andrea Gibson

Since Specialization

Citations

This map shows the geographic impact of Andrea Gibson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Gibson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Gibson more than expected).

Fields of papers citing papers by Andrea Gibson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Gibson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Gibson. The network helps show where Andrea Gibson may publish in the future.

Co-authorship network of co-authors of Andrea Gibson

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Gibson. A scholar is included among the top collaborators of Andrea Gibson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Gibson. Andrea Gibson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dawkins, Bryony, Kate Absolom, Jenny Hewison, et al.. (2024). Cost-Effectiveness of eRAPID eHealth Intervention for Symptom Management During Chemotherapy. JCO Oncology Practice. 20(4). 581–590.

Matossian, Cynthia, Michelle K. Rhee, John D. Stephens, et al.. (2024). Early Real-World Patient and Staff Experience with an Intracanalicular Dexamethasone Insert. Clinical ophthalmology. Volume 18. 1391–1401.

Warrington, Lorraine, Andrea Gibson, Rosemary Peacock, et al.. (2024). Patient and clinician perspectives of an eHealth intervention for supporting cancer treatment in the UK: mixed methods evaluation of the eRAPID randomised controlled trial. BMJ Open. 14(11). e078283–e078283.

Modi, Yasha S., et al.. (2023). Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion. Eye. 37(16). 3423–3428. 3 indexed citations

Schallhorn, Julie M., Jeffrey Nau, Marian S. Macsai, et al.. (2023). OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2. Clinical ophthalmology. Volume 17. 725–734. 2 indexed citations

Sheppard, John D., Paul Karpecki, Michael B. Raizman, et al.. (2023). Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?. Optometry and Vision Science. 100(2). 164–169. 7 indexed citations

Diana, V., Carmelina Gordon, Iván J. Suñer, et al.. (2022). Proliferative Diabetic Retinopathy Events in Patients With Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials. Journal of VitreoRetinal Diseases. 6(4). 295–301. 2 indexed citations

Katz, James A, Laura M. Periman, Enrica Sarnicola, et al.. (2022). Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease. Clinical Therapeutics. 44(11). 1463–1470. 5 indexed citations

Matossian, Cynthia, John D. Stephens, Michelle K. Rhee, et al.. (2022). Early Real-World Physician Experience with an Intracanalicular Dexamethasone Insert. Clinical ophthalmology. Volume 16. 2429–2440. 4 indexed citations

10.

Epitropoulos, Alice, Sheraz M. Daya, Cynthia Matossian, et al.. (2022). OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use. Clinical ophthalmology. Volume 16. 3405–3413. 2 indexed citations

11.

Absolom, Kate, Lorraine Warrington, Jenny Hewison, et al.. (2021). Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy. Journal of Clinical Oncology. 39(7). 734–747. 152 indexed citations breakdown →

12.

Singer, Michael, Rishi P. Singh, Andrea Gibson, et al.. (2021). Association of Early Anatomic Response with Visual Function in Neovascular Age-Related Macular Degeneration. Ophthalmology. 128(11). 1657–1660. 3 indexed citations

13.

Raizman, Michael B., et al.. (2021). ONSET-2 Phase 3 Study of OC-01 Nasal Spray for the Treatment of Dry Eye Disease. Investigative Ophthalmology & Visual Science. 62(8). 1331–1331. 2 indexed citations

14.

Modi, Yasha S., et al.. (2021). Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion. Journal of VitreoRetinal Diseases. 5(6). 505–512. 2 indexed citations

15.

McLaurin, Eugene, David G. Evans, Paul J Gomes, et al.. (2021). Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. American Journal of Ophthalmology. 229. 288–300. 13 indexed citations

16.

Steinle, Nathan, et al.. (2020). Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration. Ophthalmology Retina. 5(2). 141–150. 18 indexed citations

17.

Warrington, Lorraine, Kate Absolom, Patricia Holch, et al.. (2019). Online tool for monitoring adverse events in patients with cancer during treatment (eRAPID): field testing in a clinical setting. BMJ Open. 9(1). e025185–e025185. 27 indexed citations

18.

Jaffe, Glenn J., Peter K. Kaiser, Desmond Thompson, et al.. (2016). Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. Ophthalmology. 123(9). 1856–1864. 53 indexed citations

19.

Brown, David M., Quan Dong Nguyen, Roman G. Rubio, et al.. (2011). Ranibizumab for Diabetic Macular Edema (DME): 24-Month Efficacy and Safety Results of RISE - a Phase 3 Randomized Controlled Trial. Investigative Ophthalmology & Visual Science. 52(14). 6647–6647. 1 indexed citations

20.

Fung, Anne E., et al.. (2008). Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies. Ophthalmology. 116(2). 286–296.e4. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact